Brad Canino
Stock Analyst at Guggenheim
(4.10)
# 368
Out of 5,150 analysts
26
Total ratings
56.52%
Success rate
15.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brad Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Buy | $72 → $68 | $14.35 | +373.87% | 2 | Feb 27, 2026 | |
| GLTO Galecto | Maintains: Buy | $36 → $40 | $29.68 | +34.77% | 3 | Feb 17, 2026 | |
| CGEM Cullinan Therapeutics | Initiates: Buy | $30 | $16.30 | +84.05% | 1 | Feb 2, 2026 | |
| CBIO Crescent Biopharma | Initiates: Buy | $35 | $11.49 | +204.61% | 1 | Jan 21, 2026 | |
| BDTX Black Diamond Therapeutics | Downgrades: Neutral | n/a | $2.46 | - | 2 | Dec 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $125 → $155 | $102.67 | +50.97% | 2 | Nov 18, 2025 | |
| PYXS Pyxis Oncology | Maintains: Buy | $5 → $7 | $1.49 | +369.80% | 2 | Nov 4, 2025 | |
| KYMR Kymera Therapeutics | Assumes: Buy | $90 | $86.11 | +4.52% | 1 | Nov 3, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Buy | $40 | $15.38 | +160.08% | 2 | Oct 22, 2025 | |
| CGON CG Oncology | Initiates: Buy | $90 | $61.57 | +46.18% | 1 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $24.34 | -17.83% | 1 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $112.18 | -1.94% | 1 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $18 | $13.51 | +33.23% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $15 | $10.15 | +47.78% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $3.09 | +158.90% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $8.55 | - | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $25.23 | +117.99% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $41.69 | -28.04% | 2 | Mar 31, 2021 |
Janux Therapeutics
Feb 27, 2026
Maintains: Buy
Price Target: $72 → $68
Current: $14.35
Upside: +373.87%
Galecto
Feb 17, 2026
Maintains: Buy
Price Target: $36 → $40
Current: $29.68
Upside: +34.77%
Cullinan Therapeutics
Feb 2, 2026
Initiates: Buy
Price Target: $30
Current: $16.30
Upside: +84.05%
Crescent Biopharma
Jan 21, 2026
Initiates: Buy
Price Target: $35
Current: $11.49
Upside: +204.61%
Black Diamond Therapeutics
Dec 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.46
Upside: -
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $125 → $155
Current: $102.67
Upside: +50.97%
Pyxis Oncology
Nov 4, 2025
Maintains: Buy
Price Target: $5 → $7
Current: $1.49
Upside: +369.80%
Kymera Therapeutics
Nov 3, 2025
Assumes: Buy
Price Target: $90
Current: $86.11
Upside: +4.52%
Summit Therapeutics
Oct 22, 2025
Reiterates: Buy
Price Target: $40
Current: $15.38
Upside: +160.08%
CG Oncology
Oct 8, 2025
Initiates: Buy
Price Target: $90
Current: $61.57
Upside: +46.18%
Oct 8, 2025
Initiates: Buy
Price Target: $20
Current: $24.34
Upside: -17.83%
Sep 22, 2025
Initiates: Buy
Price Target: $110
Current: $112.18
Upside: -1.94%
Sep 4, 2025
Assumes: Buy
Price Target: $18
Current: $13.51
Upside: +33.23%
Sep 4, 2025
Assumes: Buy
Price Target: $15
Current: $10.15
Upside: +47.78%
Sep 4, 2025
Initiates: Buy
Price Target: $8
Current: $3.09
Upside: +158.90%
Sep 4, 2025
Initiates: Neutral
Price Target: n/a
Current: $8.55
Upside: -
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $25.23
Upside: +117.99%
Mar 31, 2021
Initiates: Outperform
Price Target: $30
Current: $41.69
Upside: -28.04%